These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2624884)

  • 1. Mathematical models and individualized outcome estimates in multiple sclerosis.
    Confavreux C; Wolfson C
    Biomed Pharmacother; 1989; 43(9):675-80. PubMed ID: 2624884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvements to a simple Markov model of the natural history of multiple sclerosis. I. Short-term prognosis.
    Wolfson C; Confavreux C
    Neuroepidemiology; 1987; 6(3):101-15. PubMed ID: 3658079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Markov model of the natural history of multiple sclerosis.
    Wolfson C; Confavreux C
    Neuroepidemiology; 1985; 4(4):227-39. PubMed ID: 3835484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival chance in papillary thyroid cancer in Hungary: individual survival probability estimation using the Markov method.
    Esik O; Tusnády G; Daubner K; Németh G; Füzy M; Szentirmay Z
    Radiother Oncol; 1997 Sep; 44(3):203-12. PubMed ID: 9380818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of multiple sclerosis patients in the Belgrade population.
    Pekmezovic T; Jarebinski M; Drulovic J; Stojsavljevic N; Levic Z
    Neuroepidemiology; 2002; 21(5):235-40. PubMed ID: 12207151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models.
    Riise T; Grønning M; Aarli JA; Nyland H; Larsen JP; Edland A
    J Clin Epidemiol; 1988; 41(10):1031-6. PubMed ID: 3193137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for survival in multiple sclerosis.
    Lević ZM; Dujmović I; Pekmezović T; Jarebinski M; Marinković J; Stojsavljević N; Drulović J
    Mult Scler; 1999 Jun; 5(3):171-8. PubMed ID: 10408717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A counting process approach to the analysis of the course of non-Hodgkin's lymphoma.
    Mau J; Steinke B
    Stat Med; 1986; 5(5):491-5. PubMed ID: 3787001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural history of multiple sclerosis: a regional study with some longitudinal data.
    Miller DH; Hornabrook RW; Purdie G
    J Neurol Neurosurg Psychiatry; 1992 May; 55(5):341-6. PubMed ID: 1602305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple stochastic sickness-death model.
    Mustafa AF
    Popul Sci; 1982; (3):11-28. PubMed ID: 12266212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stochastic trees: a new technique for temporal medical decision modeling.
    Hazen GB
    Med Decis Making; 1992; 12(3):163-78. PubMed ID: 1513207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis.
    Bergamaschi R; Berzuini C; Romani A; Cosi V
    J Neurol Sci; 2001 Aug; 189(1-2):13-21. PubMed ID: 11535229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: a comparison of the latent periods of different populations.
    Wolfson C; Wolfson DB; Veri JP; Confavreux C
    Neuroepidemiology; 1993; 12(5):300-6. PubMed ID: 7741823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada.
    Kingwell E; van der Kop M; Zhao Y; Shirani A; Zhu F; Oger J; Tremlett H
    J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):61-6. PubMed ID: 21865212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A flexible mixed-effect negative binomial regression model for detecting unusual increases in MRI lesion counts in individual multiple sclerosis patients.
    Kondo Y; Zhao Y; Petkau J
    Stat Med; 2015 Jun; 34(13):2165-80. PubMed ID: 25784219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disability evolution in multiple sclerosis: how to deal with missing transition times in the Markov model?
    Petiot V; Quantin C; Le Teuff G; Chavance M; Binquet C; Abrahamowicz M; Moreau T
    Neuroepidemiology; 2007; 28(1):56-64. PubMed ID: 17215588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network condition simulator for benchmarking sewer deterioration models.
    Scheidegger A; Hug T; Rieckermann J; Maurer M
    Water Res; 2011 Oct; 45(16):4983-94. PubMed ID: 21803394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A stochastic model of tumor angiogenesis.
    Mohammadi B; Haghpanah V; Larijani B
    Comput Biol Med; 2008 Sep; 38(9):1007-11. PubMed ID: 18722598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.
    Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; Al MJ; Feenstra TL
    Value Health; 2011 Dec; 14(8):1039-47. PubMed ID: 22152172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
    Boher JM; Pujol JL; Grenier J; Daurès JP
    Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.